

The 13th Annual Meeting of Asian Organization for Crohn's & Colitis (AOCC2025)

**Evening Seminar 3** 

# Cutting-edges of Ulcerative Colitis Treatments focusing on Introduction of Oral Advanced Therapy

Date 2025. 7.11 FRI 17:00-17:50

Venue

Room1

Makuhari Messe International Conference Hall 2F Convention Hall A 2-1,Nakase,Mihama-ku,Chiba City, Chiba,261-8550,Japan



#### Hiroshi Nakase, MD, PhD

Professor and Chair, Department of Gastroenterology and Hepatology, Sapporo Medical University School of Medicine



### Ken Takeuchi, MD, PhD

Director of Gastroenterology, Manager of IBD Centre Tsujinaka Hospital Kashiwanoha



### David T. Rubin, MD

Chief of the Section of Gastroenterology, Hepatology & Nutrition and the Director of the Inflammatory Bowel Disease Center at The University of Chicago Medicine

\[
\infty \text{Light refreshments will be provided for participants(limited availability)
\]

Co-sponsored: The 13th Annual Meeting of Asian organization for Crohn's & Colitis (AOCC2025) \ Pfizer Japan Inc.



Etrasimod is an oral, once daily, selective sphingosine 1-phosphate1,4,5 (S1P) receptor modulator for the treatment of moderately to severely active ulcerative colitis\*



## Pfizer Japan Inc. Exhibition Booth Information

Event Period | July 10-12, 2025

Exhibit Details at the Booth

At the Pfizer booth, we are pleased to present our pharmaceutical formulations, along with a selection of beverages inspired by countries where VEL has received approval. We warmly invite you to visit us.



**Booth location** 

Makuhari Messe International Conference Hall 2F

